Co-Authors
This is a "connection" page, showing publications co-authored by Hendrik Schulze-Koops and Rebecca Hasseli.
Connection Strength
1.434
-
[German registry www.Covid19-Rheuma.de : Status report after 1 year of the pandemic]. Z Rheumatol. 2021 Sep; 80(7):641-646.
Score: 0.238
-
Do patients with rheumatoid arthritis show a different course of COVID-19 compared to patients with spondyloarthritis? Clin Exp Rheumatol. 2021 May-Jun; 39(3):639-647.
Score: 0.234
-
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021 01; 7(1).
Score: 0.230
-
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open. 2020 09; 6(2).
Score: 0.225
-
Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci et al. Ann Rheum Dis. 2020 Aug 04.
Score: 0.224
-
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis. 2021 05; 80(5):e67.
Score: 0.222
-
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
Score: 0.059